^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Excerpt:
...- Eligible participants have tumors that show mutant or amplified EGFR....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

YAP/TAZ transcriptional co-activators create therapeutic vulnerability to verteporfin in EGFR mutant glioblastoma

Published date:
11/10/2020
Excerpt:
...the benzoporphyrin derivative verteporfin, a disruptor of YAP/TAZ-TEAD mediated transcription, preferentially induced apoptosis of cultured patient-derived EGFR-amplified/mutant GBM cells, suppressed expression of YAP/TAZ transcriptional targets, including EGFR, and conferred significant survival benefit in an orthotopic xenograft GBM model....Together, our data suggest that verteporfin is a promising therapeutic agent for EGFR amplified and mutant GBM.
DOI:
10.1158/1078-0432.CCR-20-0018